BioSpace News Archive

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2023.

The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, payable on September 29, 2023 to holders of record on September 8, 2023.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2023 financial results after the close of the U.S. financial markets on Tuesday, August 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.

Bruker Corporation announced it will report second quarter 2023 financial results before market opening on Thursday, August 3, 2023.

KC can lead to significant vision loss or even a corneal transplant; eye rubbing is a cause and symptom

Zynerba Pharmaceuticals, Inc. announced that the new date for the adjourned 2023 Annual Meeting of Stockholders is August 11, 2023 at 9:00 a.m. EDT.

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced that it has installed its 100th MERSCOPE instrument in the Single Cell Genomics Core at the Baylor College of Medicine Department of Molecular and Human Genetics led by Dr. Rui Chen.

Hoth Therapeutics, Inc. today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

Vital Biosciences introduced its revolutionary new product, the VitalOne.

Avenue Therapeutics, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (“FDA”) on key elements of the Phase 3 safety study, including the primary endpoint and statistical analysis approach, for intravenous (IV) tramadol.